Singapore
Building the world's largest multi-ethnic Asia microbiome database- http://amili.asia/ Assoc Prof Jeremy Lim’s [MBBS, MPH, MRCS (Edinburgh), MMed (Surgery), FAMS, Fulbright 2002/3] primary role is as CEO and Co-Founder of AMILI, a microbiome insights company based in Singapore serving the region. Beyond this, he also undertakes academic and practice-focused work in health financing and translation of research into impact. In previous roles, Jeremy has spent substantial time in public and private healthcare across Asia as well as in policy advisory with Singapore and other regional governments, the Asian Development Bank, the World Bank and the World Health Organization. He was founding Partner in NYSE-listed Oliver Wyman’s Asia healthcare consulting practice and remains as a Senior Advisor. Other than AMILI, he is adjunct faculty in the National University of Singapore and Monash University Malaysia. Outside academia, Jeremy serves on the boards of various for-profit and not-for-profit organizations in different aspects of healthcare including hospitals, migrant worker health, healthy longevity and digital health interventions. He maintains an active interest in health advisory, supporting former clients, focusing mainly on healthcare acquisitions and health insurance. He trained in surgery and public health, attaining post-graduate qualifications in both from the UK and US.
Advancing human health through microbiome science
Support translation of research and development into impact, meaning spin out companies, out licensing arrangements, policy and practice changes Focus on health technologies, digital health and microbiome science
Support Equitech Collective with advice, introductions and partnerships structuring